Combination of Metformin With Gefitinib to Treat NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

December 31, 2017

Study Completion Date

June 4, 2018

Conditions
NSCLCEGFR Gene AmplificationAdvanced CancerStage IIIB NSCLCStage IV NSCLC
Interventions
DRUG

Gefitinib and Metformin

Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.

DRUG

Gefitinib and placebo

Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.

Trial Locations (1)

400042

Department of Respiratory Diseases, Daping Hospital, Third Military Medical University, Chongqing

All Listed Sponsors
lead

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

OTHER

NCT01864681 - Combination of Metformin With Gefitinib to Treat NSCLC | Biotech Hunter | Biotech Hunter